What the Study Found (In Plain English)
Published in ESMO open (2025), this phase iii randomized trial evaluating 461 human participants investigated: Treatment toxicity and disease-related symptoms of metastatic colorectal cancer (mCRC) can adversely affect quality of life (QoL). Key clinical takeaway: Fruquintinib provides a clinically meaningful quality-adjusted survival benefit versus placebo in refractory mCRC.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (ESMO open, 2025-03-15; N = 461; Rigor 93/100): Fruquintinib provides a clinically meaningful quality-adjusted survival benefit versus placebo in refractory mCRC.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.